• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Breaking NEWS - TearCare from Sight Sciences

















Still no payor policy. Lol. Still. I coverage. How’s that market access strategy going??!!


Hahahaha. Never!!

hey Mike and Stacie

how’s your market access team doing on those tearcare policies? They are crushing it!!

omg the commercial and Medicare wins are massive

hahahahahaha. Ahhhhhhahahaha
 








They market access team just told the organization they have fair balanced payment from 2 MAC’s

no one believes them. They say they are getting so much done and they are not doing didlly.
 




















1 fake reimbursement not even the value of tear care reimbursed 1 time by a MAC. You call that market access success?

This place lies all day long to make try and Paul badwani and his private equity gain inflated numbers.

This place is FRAUD